Ceribell, Inc. Files S-1/A for IPO

Ticker: CBLL · Form: S-1/A · Filed: Sep 19, 2024 · CIK: 1861107

Ceribell, INC. S-1/A Filing Summary
FieldDetail
CompanyCeribell, INC. (CBLL)
Form TypeS-1/A
Filed DateSep 19, 2024
Risk Levelmedium
Pages15
Reading Time18 min
Key Dollar Amounts$2 billion, $45.2 million, $25.9 million, $29.7 million, $20.5 million
Sentimentneutral

Sentiment: neutral

Topics: ipo, sec-filing, amendment

TL;DR

Ceribell IPO update: S-1/A filed 9/19. Looks like they're still aiming for the public market.

AI Summary

Ceribell, Inc. filed an S-1/A amendment on September 19, 2024, for its initial public offering. The company, incorporated in Delaware, is based in Sunnyvale, California, and operates in the electromedical apparatus sector. Jane Chao, Ph.D., is the President, CEO, and Co-Founder.

Why It Matters

This filing indicates Ceribell, Inc. is moving forward with its plan to become a publicly traded company, which could impact its ability to raise capital and its future growth trajectory.

Risk Assessment

Risk Level: medium — As an S-1/A filing, it represents a company seeking to go public, which inherently carries risks associated with market reception and financial performance.

Key Numbers

Key Players & Entities

FAQ

What is the purpose of this S-1/A filing?

This is an amendment (S-1/A) to Ceribell, Inc.'s initial registration statement (Form S-1), indicating updates or changes to their planned initial public offering.

When was this amendment filed?

The amendment was filed on September 19, 2024.

Who is the principal executive officer of Ceribell, Inc.?

Jane Chao, Ph.D., is the President, Chief Executive Officer and Co-Founder of Ceribell, Inc.

What is Ceribell, Inc.'s primary business classification?

Ceribell, Inc. is classified under Standard Industrial Classification code 3845, which is ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS.

Where is Ceribell, Inc. headquartered?

Ceribell, Inc.'s principal executive offices are located at 360 N. Pastoria Avenue, Sunnyvale, California 94085.

Filing Stats: 4,386 words · 18 min read · ~15 pages · Grade level 15.4 · Accepted 2024-09-19 16:32:01

Key Financial Figures

Filing Documents

Description of Capital Stock

Description of Capital Stock 159 Special Note Regarding Forward-Looking Statements 58 Shares Eligible for Future Sale 164 Material U.S. Federal Income Tax Consequences to Non-U.S. Holders 167 Market and Industry Data 60

Use of Proceeds

Use of Proceeds 61

UNDERWRITING

UNDERWRITING 170 Dividend Policy 62 Legal Matters 177 Capitalization 63 Experts 177

Dilution

Dilution 65 Where You Can Find Additional Information 177 Management’s Discussion and Analysis of Financial Condition and Results of Operations 68 CHANGE IN INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM 177

Business

Business 87 Index to Financial Statements F- 1 Management 134 As used in this prospectus, unless the context otherwise requires, references to “Ceribell,” the “company,” “we,” “us,” and “our” refer to CeriBell, Inc. “Ceribell,” the Ceribell logos, and other trade names, trademarks, or service marks of Ceribell appearing in this prospectus are the property of Ceribell. Other trade names, trademarks, or service marks appearing in this prospectus are the property of their respective holders. We do not intend our use or display of other companies’ trade names, trademarks, or service marks to imply a relationship with, or endorsement or sponsorship of us, by these other companies. Solely for convenience, trade names, trademarks, and service marks referred to in this prospectus appear without the , , and SM symbols, but those references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or that the applicable owner will not assert its rights, to these trade names, trademarks, and service marks. Numerical figures included in this prospectus have been subject to rounding adjustments. Accordingly, numerical figures shown as totals in various tables may not be arithmetic aggregations of the figures that precede them. We have not, and the underwriters have not, authorized anyone to provide you any information or to make any representations other than those contained in this prospectus or in any free writing prospectus prepared by or on behalf of us or to which we have referred you. Neither we nor the underwriters take responsibility for, or provide any assurance as to the reliability of, any other information others may give you. This prospectus is an offer to sell only the shares offered hereby, and only under circumstances and in jurisdictions where it is lawful to do so. We are not, and the underw

View Full Filing

View this S-1/A filing on SEC EDGAR

View on Read The Filing